Maedica · 2026
A Randomized Clinical Study to Compare the Effectiveness of the Orthoptek Magnocellular Stimulator, Occlu-tab and Phakic Intraocular Lens in Refractive Amblyopia of Older Children and Young Adults.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Morya Arvind Kumar, Shah Mehul, Shah Shreya, Sinha Aprajita, Gopal K S Santhan
Аннотация
BACKGROUND: The conventional management modality of refractive amblyopia is patching of the normal eye, which has high recurrence rates. Modern technological advancements have the potential to offer comprehensive visual rehabilitation and improvement in binocular single vision.
AIMS: To compare the clinical efficacy of three novel interventions - Phakic intraocular lens (IOL), Occlu-tab and Orthoptek Magnocellular Stimulator - in managing refractive amblyopia in adolescents and young adults.
METHODS: Young adults with refractive amblyopia who did not respond to occlusion therapy were randomized into three groups: Occlu-tab, Orthoptek and Phakic IOL. Pre- and post-treatment best-corrected visual acuity (BCVA), contrast sensitivity and stereoacuity were assessed.
RESULTS: All three modalities produced significant within-group improvements in BCVA, contrast sensitivity and stereoacuity (p < 0.001). Best-corrected visual acuity improved comparably across the three groups, including Orthoptek (mean gain 0.44), Occlu-tab (0.34) and Phakic IOL (0.29 logMAR). There was no statistically significant difference between groups (p = 0.136). Contrast sensitivity gains were higher for Occlu-tab (+0.78) and Orthoptek (+0.78) than for Phakic IOL (+0.59), with a significant between-group difference (p = 0.003). Stereoacuity has markedly improved with Occlu-tab (715.62 sec arc) and Orthoptek (713.54 sec arc) versus less improvement with a Phakic IOL (312.50 sec arc), with the between-group difference being highly significant (p < 0.001).
CONCLUSION: In terms of final binocular functional success rates, Orthoptek and Occlu-tab therapies were superior as compared to Phakic IOLs. A combination of amblyopia therapies should be the approach in the near future.
AIMS: To compare the clinical efficacy of three novel interventions - Phakic intraocular lens (IOL), Occlu-tab and Orthoptek Magnocellular Stimulator - in managing refractive amblyopia in adolescents and young adults.
METHODS: Young adults with refractive amblyopia who did not respond to occlusion therapy were randomized into three groups: Occlu-tab, Orthoptek and Phakic IOL. Pre- and post-treatment best-corrected visual acuity (BCVA), contrast sensitivity and stereoacuity were assessed.
RESULTS: All three modalities produced significant within-group improvements in BCVA, contrast sensitivity and stereoacuity (p < 0.001). Best-corrected visual acuity improved comparably across the three groups, including Orthoptek (mean gain 0.44), Occlu-tab (0.34) and Phakic IOL (0.29 logMAR). There was no statistically significant difference between groups (p = 0.136). Contrast sensitivity gains were higher for Occlu-tab (+0.78) and Orthoptek (+0.78) than for Phakic IOL (+0.59), with a significant between-group difference (p = 0.003). Stereoacuity has markedly improved with Occlu-tab (715.62 sec arc) and Orthoptek (713.54 sec arc) versus less improvement with a Phakic IOL (312.50 sec arc), with the between-group difference being highly significant (p < 0.001).
CONCLUSION: In terms of final binocular functional success rates, Orthoptek and Occlu-tab therapies were superior as compared to Phakic IOLs. A combination of amblyopia therapies should be the approach in the near future.